Nika Pharmaceuticals is an early-stage pharmaceutical and dietary supplement company that licenses drug candidates and nutritional products — primarily from Bulgarian research entities — and aims to commercialize them across global markets. Rather than conducting its own research, Nika acquires exclusive rights to third-party developed products, then funds their regulatory registration, production, and distribution. The company's lead drug candidate is Thymus Nuclear Glycoprotein (TNG), a prescription drug being developed for HIV/AIDS treatment, for which Nika holds a 15-year exclusive production and distribution agreement. Nika is also developing Inactivated Pepsin Fraction (IPF), a drug platform backed by five U.S. patents, jointly with Immunotech Laboratories BG. In dietary supplements, Nika holds exclusive production and sales rights across multiple global territories for a portfolio of eight products, including Carotilen and Physiolong. Nika has not commercialized any products yet. Production is intended to flow through Nika Europe, in which Nika holds an 80% controlling interest, which is planning to build a pharmaceutical manufacturing facility. The company was incorporated in Colorado in 2000, pivoted to its current focus in 2022, and trades on the OTCQB under the ticker NIKA.